What is the Current Clinical Impact of the CYP2CTG Haplotype?
Authorized Users Only
2024
Authors
Ingelman-Sundberg, MagnusJukić, Marin
Bråten, Line Skute
Kringen, Marianne Kristiansen
Molden, Espen
Contribution To Periodical (Published version)
Metadata
Show full item recordAbstract
We read with great interest the paper by Zubiaur et al.1 on the analysis of a genotype–phenotype relationship of the CYP2C:TG haplotype. This study, including 225 patients receiving one of 6 different drugs and liver pieces from 135 children (median age 7 years), is in contrast to 2 studies by Bråten et al. using in vivo data from 875 escitalopram-treated2 and 840 sertraline-treated3 Norwegian patients, respectively, in which significantly increased rate (+20 to 25%) of CYP2C19-dependent metabolism of these drugs was found for the CYP2C:TGhaplotype.
Source:
Clinical Pharmacology and Therapeutics, 2024, 115, 2, 183-183Publisher:
- John Wiley and Sons Inc
DOI: 10.1002/cpt.3094
ISSN: 0009-9236
PubMed: 37984075
WoS: 001107388700001
Scopus: 2-s2.0-85177230656
Collections
Institution/Community
PharmacyTY - JOUR AU - Ingelman-Sundberg, Magnus AU - Jukić, Marin AU - Bråten, Line Skute AU - Kringen, Marianne Kristiansen AU - Molden, Espen PY - 2024 UR - https://farfar.pharmacy.bg.ac.rs/handle/123456789/5300 AB - We read with great interest the paper by Zubiaur et al.1 on the analysis of a genotype–phenotype relationship of the CYP2C:TG haplotype. This study, including 225 patients receiving one of 6 different drugs and liver pieces from 135 children (median age 7 years), is in contrast to 2 studies by Bråten et al. using in vivo data from 875 escitalopram-treated2 and 840 sertraline-treated3 Norwegian patients, respectively, in which significantly increased rate (+20 to 25%) of CYP2C19-dependent metabolism of these drugs was found for the CYP2C:TGhaplotype. PB - John Wiley and Sons Inc T2 - Clinical Pharmacology and Therapeutics T1 - What is the Current Clinical Impact of the CYP2CTG Haplotype? VL - 115 IS - 2 SP - 183 EP - 183 DO - 10.1002/cpt.3094 ER -
@article{ author = "Ingelman-Sundberg, Magnus and Jukić, Marin and Bråten, Line Skute and Kringen, Marianne Kristiansen and Molden, Espen", year = "2024", abstract = "We read with great interest the paper by Zubiaur et al.1 on the analysis of a genotype–phenotype relationship of the CYP2C:TG haplotype. This study, including 225 patients receiving one of 6 different drugs and liver pieces from 135 children (median age 7 years), is in contrast to 2 studies by Bråten et al. using in vivo data from 875 escitalopram-treated2 and 840 sertraline-treated3 Norwegian patients, respectively, in which significantly increased rate (+20 to 25%) of CYP2C19-dependent metabolism of these drugs was found for the CYP2C:TGhaplotype.", publisher = "John Wiley and Sons Inc", journal = "Clinical Pharmacology and Therapeutics", title = "What is the Current Clinical Impact of the CYP2CTG Haplotype?", volume = "115", number = "2", pages = "183-183", doi = "10.1002/cpt.3094" }
Ingelman-Sundberg, M., Jukić, M., Bråten, L. S., Kringen, M. K.,& Molden, E.. (2024). What is the Current Clinical Impact of the CYP2CTG Haplotype?. in Clinical Pharmacology and Therapeutics John Wiley and Sons Inc., 115(2), 183-183. https://doi.org/10.1002/cpt.3094
Ingelman-Sundberg M, Jukić M, Bråten LS, Kringen MK, Molden E. What is the Current Clinical Impact of the CYP2CTG Haplotype?. in Clinical Pharmacology and Therapeutics. 2024;115(2):183-183. doi:10.1002/cpt.3094 .
Ingelman-Sundberg, Magnus, Jukić, Marin, Bråten, Line Skute, Kringen, Marianne Kristiansen, Molden, Espen, "What is the Current Clinical Impact of the CYP2CTG Haplotype?" in Clinical Pharmacology and Therapeutics, 115, no. 2 (2024):183-183, https://doi.org/10.1002/cpt.3094 . .